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INTRODUCTION
High-dose chemotherapy with autologous stem cell trans-
plantation is increasingly used in a wide range of hematolog-
ic and solid malignancies and several trials have suggested that
this strategy is effective in patients with aggressive lymphoma
(1) and multiple myeloma (2). Peripheral blood progenitor
cells (PBPC) have almost completely replaced bone marrow
as the source of stem cells because of easier accessibility, faster
engraftment, and possibly lower tumor contamination (3-5).
As a result of this change in practice, there are currently an
increasing number of patients undergoing PBPC mobiliza-
tion therapy and subsequent leukapheresis.
Successful autologous peripheral blood stem cell transplan-
tation (PBSCT) depends on the infusion of an adequate num-
ber of PBPC to achieve rapid and durable hematologic recov-
ery. The infusion of≥2.5×106 CD34+ cells per kg of body
weight (/kg) is generally considered to be sufficient to induce
stable hematologic engraftment within a reasonable time. The
transplantation of ≥5×106 CD34+cells/kg results in a faster
hematopoietic recovery, particularly of the megakaryocytic
lineage (6). 
The timing of PBPC collection is important to maximize
the number of progenitors harvested with the fewest apheresis
procedures. For operational and economical efficiency, it would
clearly be beneficial if sufficient PBPC could be obtained from
the fewest collections and the optimal timing of these leuka-
phereses could be reliably predicted. A further benefit of a
higher CD34+ cell yield per single apheresis is reduction in
the total volume of the progenitor cell component. Besides
the decrease in the contaminating RBCs within the graft (7),
a reduction in the total volume of the PBPC component may
reduce the amount of dimethyl sulfoxide required for cryo-
preservation (8). Both factors diminish the risk of adverse
side effects related to the graft transfusion. 
The most reliable time for harvesting PBPC is yet to be de-
termined. Several different predictors for PBPC yield have been
used for the timing of apheresis. Circulating progenitor cells
(CFU-GM) cannot be used for this purpose because it takes
about 2 weeks to form enumerable colonies and is difficult
to standardize. Following a chemotherapy nadir, the periph-
eral blood (PB) WBC count has been used to indicate when
leukapheresis should be commenced. The collections are usu-
ally initiated when the WBC count recovers to greater than
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Clinical Usefulness of the Hematopoietic Progenitor Cell Counts in
Predicting the Optimal Timing of Peripheral Blood Stem Cell Harvest
Although enumeration of CD34+ cells in the peripheral blood (PB) on the day of
apheresis predicts the quantity of those cells collected, the flow cytometric tech-
niques used are complex and expensive, and several hours are required to obtain
the result in the clinical practice setting. The Sysmex SE-9000 automated haema-
tology analyzer provides an estimate of immature cells, called hematopoietic pro-
genitor cells (HPC). The aim of this study was to evaluate the clinical usefulness
of HPC in predicting the optimal timing of peripheral blood progenitor cells (PBPC)
harvest. Studies were performed on 628 aphereses from 160 patients with hema-
tologic or solid malignancies. Spearman’ s rank statistics was used to assess cor-
relation between HPC, WBC, mononuclear cells (MNC), and CD34+ cells. A receiv-
er operating characteristic (ROC) curve was drawn for cutoff value of HPC, and
predictive values of the chosen cutoff value of HPC for different target CD34+ cell
collections were calculated. The PB HPC had a stronger correlation ( =0.592, p<
0.001) with collected CD34+ cells than did PB WBC and PB MNC. The ROC curve
showed that the best cutoff value of HPC was 50×10
6/L for the target CD34+ cells
≥1×10
6/kg with sensitivity of 75%. Positive and negative predictive values of
HPC≥50×10
6/L for CD34+ cells≥1×10
6/kg were 59.7% and 81.1%, respective-
ly. In the clinical practice setting, applying variable cutoff values of HPC would be
a useful tool to predict the optimal timing of PBPC collection.
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1×109/L (9). However, other studies have suggested that wait-
ing until the WBC count is greater than 2-10×109/L may
be advantageous (10, 11). Furthermore, there is little corre-
lation between the PB WBC count and the number of CD34+
cells in a leukapheresis product, resulting in inefficient col-
lections and increasing the overall cost of obtaining PBPC for
the transplant (12-15). While enumeration of CD34+ cells
in the PB before apheresis predicts the quantity of those cells
collected (16-18), the flow cytometric techniques used are com-
plex and expensive. Also, several hours are usually required to
obtain the result, which complicates patient management in
the clinical practice setting. A simple, faster, and less expensive
alternative method should therefore be pursued, especially in
the countries with limited medical budget.
Sysmex has developed an automated hematology analyzer
(Sysmex SE9000, TOA Medical Electronica Co. Ltd. Japan)
that detects a small population of immature white blood cells,
hematopoietic progenitor cells (HPC), with the use of special
equipment called the immature myeloid information (IMI)
channel (19). We have previously reported on the preliminary
data, which included 32 patients, of the correlation between
the number of PB HPC and collected CD34+cells (20). In the
present study, we evaluated potential usefulness of PB HPC
count in the clinical practice through the analysis of the data
on 160 consecutive patients. We report the kinetics of PB
HPC and CD34+ cells in apheresis products, the correlation
between the PB HPC and collected CD34+ cells, sensitivity,
specificity, and predictive values of HPC for variable target of
CD34+ cells collection, and the clinical usefulness of HPC to
judge apheresis commencement. 
MATERIALS AND METHODS
Patients
Between July 1998 and April 2002, 160 consecutive pa-
tients with hematologic or solid malignancies who were eligi-
ble for autologous PBSCT underwent PBPC harvests at our
institution. Prior to beginning PBPC mobilization and har-
vest, all patients had given signed informed consent approved
by the institutional review board of Asan Medical Center.
PBPC mobilization and harvest
Forty-one patients with multiple myeloma, 31 patients with
lymphoma, 20 patients with breast cancer, and 3 patients with
other malignancies were mobilized with cyclophosphamide
(Cy) 2-4 g/m
2 with G-CSF (NeutroginTM, Choongwae Ltd,
Seoul, Korea). Seven patients were primed with G-CSF alone.
Others were mobilized with various chemotherapy regimens
that were chosen both for their efficacy against the patients’
disease and their ability to induce a WBC rebound follow-
ing marrow aplasia. For patients mobilized with Cy or chemo-
therapy, the first dose of G-CSF was given subcutaneously
at a dose of 5-10  g/kg/day from the day of nadir of the WBC
count after Cy or other chemotherapy had ended and contin-
ued until the day before the last leukapheresis. The first PBPC
harvest was performed on the day when the WBC count ex-
ceeded 10.0×109/L or MNC count exceeded 1.0×109/L for
patients mobilized with Cy or chemotherapy. It was under-
taken on the 4th to 5th day of G-CSF administration if no
chemotherapy was used. 
PBPC were collected with a continuous-flow blood cell sep-
arator (Fenwal CS3000 plus, Baxter healthcare, Deerfield, IL,
U.S.A.). Each apheresis procedure was performed for approx-
imately 2 to 4 hr, processing 10-14 L of whole blood volume.
The total MNC count and CD34+ count of the leukaphere-
sis product were monitored daily following each collection.
Leukapheresis was continued until analysis of the component
confirmed the collection of≥5.0×106 CD34+ cells/kg.
Measurement of HPC
Enumeration of HPC was performed using the Sysmex SE
9000. HPC were detected in the IMI channel. Detection of
HPC was made possible by the combination of a special re-
agent system and direct current (DC)/radiofrequency (RF)
biosensors. The lysis reagent (Stromatolyser-IM) contains deter-
gents that are capable of lysing more mature WBC because
of their higher membrane lipid content while HPC remains
relatively intact. Because various types of immature WBC
react differently to the reagent, they also occupy distinct areas
on the bivariate matrix of the IMI scattergram (19). Using
the purified CD34+ cells, the lower DC and RF signal were
previously identified for the HPC detection area. HPC were
reported both as an absolute number and a percentage of the
WBC in the sample.
Measurement of CD34+ cells
The quantities of CD34+ cells in the leukapheresis compo-
nent were determined by flow cytometry using FACScan (Bec-
ton Dickinson, Palo Alto, CA, U.S.A.). After lysis of RBCs
in an ammonium chloride lysis solution and washing with
phosphate-buffered saline with 0.5% human serum albumin,
100  L of cell suspension was stained with phycoerythrin (PE)-
conjugated monoclonal anti-CD34 antibody (HPCA-2, Bec-
ton Dickinson) and fluorescein isothiocyanate (FITC)-conju-
gated anti-CD14 antibody (Leu-M3, Becton Dickinson) at
the concentrations recommended by the manufacturer. After
incubation for 25 min at 4℃in the dark, additional cells were
stained with Leu-M3 and PE-conjugated IgG1 (Becton Dick-
inson) as a negative isotope control. Then the cells were washed
twice and resuspended and examined with a FACScan. A total
of 1.0×10
5 cells were analyzed by the FACScan research soft-
ware (Becton Dickinson). Hematopoietic Progenitor Cells 29
Measurement of nucleated cells in the PB and apheresis
products
WBC count in the sample was determined with Sysmex
SE9000. Differential counts were done microscopically on a
Wright stained smear. The mononuclear cell count was obtain-
ed by multiplying the number of leukocytes with the sum of
the percentage of lymphocytes and monocytes from the dif-
ferential count. 
Statistics
Patients’ characteristics and apheresis components are de-
scribed using summary statistics as median values and ranges.
Correlations between the logarithm of the number of CD34+
cells and HPC cells, WBC, MNC in the PB and apheresis
products were assessed using linear regression and Spearman’ s
rank correlation coefficient ( ). To assess the feasibility of HPC
as a diagnostic test for predicting the ability to achieve target
CD34+ cells of 1×106/kg and 2×106 cells/kg, the receiver
operating characteristic (ROC) curve was used. We calculat-
ed positive and negative predictive values of HPC, utilizing
several different cutoff points for HPC. Statistical analysis was
performed with SPSS for Windows V.10.0 (SPSS Inc, Chicago,
IL, U.S.A.). Significance levels were set at 0.05.
RESULTS
Patient characteristics
Patients’ characteristics are given in Table 1. There were 80
women and 80 men. The median age was 45 yr ranging from
15 to 68 yr. The patients with non-Hodgkin’ s lymphoma
comprised 40 percent of the patients (64/160). Other malig-
nancies included multiple myeloma in 51 patients, breast can-
cer in 33, acute myelogenous leukemia in 5, medulloblastoma
in 4, ovarian cancer in 2, and acute lymphocytic leukemia in
1 patient. Forty-one (29.3%) of 160 patients had been given
7 or more cycles of chemotherapy, and 104 (68%) patients had
a history of prior exposure to alkylating agents, which includ-
ed melphalan, BCNU, and cyclophosphamide. Twenty-two
(14%) of 160 patients had previously undergone axial skele-
tal radiotherapy.
Mobilization and collection of PBPC
A total of 628 leukaphereses were done in 160 patients
(Table 2). The median number of CD34+ cells and MNC in
a leukapheresis product was 0.65×106/kg (range, 0.01-25.62)
and 1.40×108/kg (range, 0.14-6.74), respectively. The per-
centages of leukapheresis products reaching the target yield
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Fig. 1. The kinetics of CD34+ cells in an apheresis product and
the peripheral blood HPC. Solid line, CD34+ cells; dashed line,
HPC (mean±SE).
Mobilization therapy
Cyclophosphamide+G-CSF 92
Chemotherapy+G-CSF 61
G-CSF alone 7
Total number of leukapheresis procedures 628
Number of leukapheresis  4 (2-9)*
procedure per person
Number of HPC in PB 46.64×10
6/L (0-3052.21)
Number of WBC in PB 13.10×10
9/L (0.80-55.50)
Number of MNC in PB 1.67×10
9/L (0.10-10.96)
Number of CD34+ 0.65×10
6/kg (0.01-25.62)
cell in a leukapheresis
Number of MNC in a leukapheresis 1.40×10
8/kg (0.14-6.74)
Number of total CD34+ cell collected 5.43×10
6/kg (0.03-60.16)
Number of total MNC cell collected 6.42×10
8/kg (0.72-17.73)
*Median (range). G-CSF, granulocyte-colony stimulating factor; HPC,
hematopoietic progenitor cell; MNC, mononuclear cell.
Table 2. Mobilization methods, peripheral blood nucleated cell
counts, and results of CD34+ cell collection
Age (yr), median (range) 45 (15-68)
Male:female 80:80
Disease
Breast cancer 33
NHL 64
MM 51
Others (AML, medulloblastoma, ovary cancer, ALL) 12
Previous axial skeletal RT, No (%) 22 (14%)
Cycles of prior chemotherapy, median (range) 5 (2-30)
Number of prior chemotherapy regimen
1 83 (53%)
2 56 (35%)
≥3 19 (11%)
Previous exposure to alkylating agents No. (%) 104 (68%)
NHL, non-Hodgkin’ s lymphoma; MM, multiple myeloma; AML, acute
myelogenous leukemia; ALL, acute lymphoblastic leukemia; RT, radio-
therapy.
Table 1. Patient characteristics30 J.-L. Lee, S.-B. Kim, G.-W. Lee, et al.
of CD34+ cells≥1×106/kg and 2×106/kg were 42.2% and
26.6%, respectively. The kinetics of HPC in the PB and CD
34+ cells in a leukapheresis product over the course of collec-
tion for all the patients are depicted in Fig. 1. The kinetics of
HPC in PB did not seem to parallel that of CD34+ cell in
apheresis products. A median of 5.43×106 CD34+ cells/kg
(range, 0.03-60.16) was harvested by a median of 4 (range,
2-9) apheresis procedures. CD34+cells greater than 2.5×106/
kg were harvested from 113 (71%) patients. In 47 patients
(29%) who failed to attain 2.5×10
6 CD34+ cells/kg with a
median of 4 apheresis procedures (range, 2-8), there were no
medical complications that led to discontinuation of apheresis,
and harvests were discontinued when they were not likely
to yield≥0.2×106/kg CD34+ cells per day. Thirty-four (72.3
%) of 47 patients who failed to yield≥2.5×106 CD34+cells/
kg underwent≥4 apheresis procedures. 
The correlation between cell counts in the PB and the
yield of CD34+ cells
The median number of PB HPC on the day of leukaphere-
sis was 46.6×106/L (range, 0-3052.2, Table 2). The corre-
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Fig. 2. The relationship between the collected CD34+ cells and peripheral blood nucleated cell counts. Plotted are the yield of CD34+
cells (×10
6/kg) in an apheresis product (Y-axis) versus: (A) the number of peripheral blood HPC cells (×10
6/L); (B) the number of
peripheral blood WBC counts (×10
9/L); (C) the number of peripheral blood MNC counts (×10
9/L); and (D) the number of collected MNC
(×10
8/kg) in an apheresis product (×-axis) in all apheresis procedures.
HPC (×10
6/L)sponding median numbers of peripheral blood WBC and
MNC on the day of leukapheresis were 13.10×109/L (range,
0.80-55.50) and 1.67×109/L (range, 0.1-10.96), respectively. 
The relationship between PB nucleated cell counts on the
day of apheresis and the number of CD34+cells in an aphere-
sis product is depicted in Fig. 2. The number of HPC in the
PB had a stronger correlation ( =0.592, p<0.001) with col-
lected CD34+ cell counts than did PB WBC ( =0.168, p<
0.001) and PB MNC ( =0.316, p<0.001) counts. There was
a weak correlation between collected MNC counts with col-
lected CD34+ cell counts ( =0.351, p<0.001). 
Sensitivity, specificity, and predictive values of PB HPC
counts
We calculated the HPC level in PB as a diagnostic tool for
predicting a target yield of CD34+ cells of at least 1×106/kg
and 2×106/kg. To set the cutoff value, we used a ROC curve.
The ROC curve graphically portrays the trade-offs involved
between either test’ s sensitivity and specificity. We plotted
sensitivity as a function of 1-minus-specificity, false positive
rate. The ROC curve revealed that the best cutoff point for
the most adequate sensitivity and specificity was 50×106/L
for target CD34+ cells ≥1×106/kg and 55×106/L for tar-
get CD34+ cells ≥2×106/kg (Fig. 3). The sensitivity and
specificity of that cutoff value are listed in Table 3. The cutoff
value of PB HPC and the ROC curves for each target PBPC
yield is very close, so the ability of PB HPC to discriminate
between PBPC yield ≥1×106 CD34+ cells/kg and ≥2×
106 CD34+ cells/kg is negligible. 
We calculated a positive and a negative predictive value of
HPC using several different cutoff values (80, 70, 60, 50, 20,
10, and 5×106/L). These predictive values are shown in Table
4. For patients with HPC counts ≥50×106/L, 59.7% of 263
collections reached the target CD34+cells ≥1×106/kg. The
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80` Positive PV 139/217 (64.1%) (57.7-70.5%)* 91/217 (41.9%) (35.3-48.5%)
Negative PV 247/316 (78.2%) (73.6-82.7%) 277/316 (87.7%) (84.1-91.3%)
70 Positive PV 143/227 (63.0%) (56.7-69.3%) 94/227 (41.4%) (35.0-47.8%)
Negative PV 241/306 (78.8%) (74.2-83.4%) 270/306 (88.2%) (84.6-91.8%)
60 Positive PV 150/241 (62.2%) (55.8-68.3%) 97/241 (40.2%) (34.1-46.8%)
Negative PV 219/270 (81.1%) (76.4-85.8%) 240/270 (88.9%) (85.2-92.6%)
50 Positive PV 157/263 (59.7%) (53.8-65.6%) 100/263 (38.0%) (32.1-43.9%)
Negative PV 219/270 (81.1%) (76.4-85.8%) 240/270 (88.9%) (85.2-92.6%)
20 Positive PV 184/336 (54.8%) (49.5-60.1%) 117/336 (34.8%) (29.7-39.9%)
Negative PV 173/197 (87.8%) (83.2-92.4%) 184/197 (93.4%) (89.9-96.9%)
10 Positive PV 195/390 (50.0%) (45.0-55.0%) 126/390 (32.3%) (27.7-36.9%)
Negative PV 130/143 (90.9%) (86.2-95.6%) 139/143 (97.2%) (94.5-99.9%)
5 Positive PV 200/442 (45.2%) (40.6-49.8%) 127/442 (28.7%) (24.5-32.9%)
Negative PV 83/91 (91.2%) (85.4-97.0%) 88/91 (96.7%) (93.0-100.0%)
*95% confidence interval.
Cutoff value of HPC ( L)
Target CD34+ cells
≥1×10
6/kg ≥2×10
6/kg
Table 4. The positive and negative predictive values (PV) of HPC for different target collection of CD34+cells
≥1×10
6/kg 50 75.5% (69.9-80.6%)* 68.4% (63.2-73.1%)
≥2×10
6/kg 55 75.4% (66.9-82.3%) 62.3% (57.8-67.5%)
*95% confidence interval.
Target Cutoff  value 
Sensitivity Specificity CD34+cells of HPC
Table 3. The recommended cutoff value of HPC for different
target collection of CD34+ cells with the best sensitivity and
specificity drawn from the ROC curve
1-Specificity
CD34+ cells ≥1×10
6/kg
CD34+ cells ≥2×10
6/kg
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Fig. 3. ROC curves for the peripheral blood HPC to obtain ≥1×
10
6 CD34+ cells/kg (AUC: 0.783, p<0.001) and ≥2×10
6 CD34+
cells/kg (AUC: 0.768, p<0.001). The curves have a similar
shape, so the ability to discriminate between PBPC yield ≥1×
10
6 CD34+ cells/kg and ≥ 2×10
6 CD34+ cells/kg is negligible.positive predictive values of different cutoff points of PB HPC
ranging from 5 to 80×106/L increased from 45.2% to 64.1
%; 16-fold increase in HPC elevated positive predictive value
by just 18.9%. For patients with HPC values <50×106/L,
81.1% of 270 patients did not yield target CD34+ cell ≥1
×106/kg. When we set 2×106/kg CD34+ cells/kg as the
target yield, the negative predictive value increased up to 89%,
but the positive predictive values decreased below 40%. 
Use of PB nucleated cells to decide when to commence
apheresis
Excluding the patients who were mobilized with G-CSF
alone and those whose PB nucleated cell counts were not fully
available, 6 options for deciding when to start PBPC collec-
tion were considered (Table 5). The first option was to make
a decision to start apheresis on the basis of WBC count ≥5
×109/L. Fifty-five percent (253/457) of the patients with
WBC count ≥5×109/L had poor CD34+ cell yields. Posi-
tive predictive value was just about 45%. False negative rate
was 35.6%, and only 15.7% of harvests that proved to be
inadequate would be avoided. The second option was to start
apheresis when WBC counts were above ≥10×109/L. At
this threshold, 48.5% of harvests yielded CD34+cells ≥1×
106/kg, and 43% of harvests with poor yield would be
avoided. However, 30% of yields greater than 1×106/kg
CD34+ cells would be missed. The third option was the use
of PB MNC counts. When the decision to apherese was taken
at the threshold of 1×109/L, 50.5% of the patients who fit-
ted the MNC criteria had poor PBPC yields, and 33.3% of
harvests that proved to be inadequate would be avoided.
Positive predictive value was 49.5% and false negative rate
was 25.4%. The fourth option was to base the decision to
commence apheresis on the PB HPC count. At a cutoff value
of 10×106/L, positive predictive value was 52.5% with false
negative rate of 9.1%, which was the lowest among other
options.
At a cutoff value of 20×106/L, 43.9% of the patients who
met the criteria had poor PBPC yields, and 52.0% of aphere-
ses that proved to be inadequate would be avoided. The last
option was to commence apheresis on the day of PB HPC
count ≥50×106/L. Although it had the highest positive
predictive value, 24.3% of yields greater than 1×106/kg
CD34+ cells would be missed if aphereses were not performed
because of PB HPC level <50×106/L. This option had the
lowest false positive rate, and 67.5% of harvests with poor yield
would be avoided.
DISCUSSION
The decision when to start leukapheresis is a critical issue
for the efficient and cost-effective collection of adequate PBPC
for transplantation. Many transplantation centers have used
the PB CD34+ cell counts to initiate harvesting and predict
yields (12, 15, 21, 22). This could be the most precise predic-
tor of CD34+ cell yields, but the correlation coefficients bet-
ween PB CD34+ cells and CD34+ cells in a leukapheresis
product were variable, ranging from 0.57 to 0.95 (12, 23-
25). These relatively inconsistent correlations can be caused
by technical difficulties in the harvesting procedure or inac-
curacies in the blood CD34+ measurements, especially when
the PB CD34+ percentage is low. In addition, the techniques
to enumerate CD34+ cells are complex, expensive, require
technical skills, and reporting the results may take several
hours, often resulting in a 1-day delay before apheresis can
be started in the clinical practice setting. 
We evaluated the clinical usefulness of the HPC count, enu-
merated by Sysmex SE-9000 automated hematology analyz-
er, for optimizing stem cell yields. This is rapid and incurs no
cost beyond that of a blood count. The detection of HPC is
possible through the IMI channel that uses DC and RF to
count cells after incubation with a specific lysate designed to
lyse red cells and mature white blood cells, leaving only imma-
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WBC≥5×10
9/L Yes (n=457) 204 (44.6%)*(88.7%)
� 253 (55.4%) (84.3%)
No (n=73) 26 (35.6%) (11.3%) 47 (64.4%) (15.7%)
WBC≥10×10
9/L Yes (n=332) 161 (48.5%) (70%) 171 (51.5%) (57.0%)
No (n=198) 69 (34.8%) (30%) 129 (65.2%) (43.0%)
MNC≥1×10
9/L Yes (n=396) 196 (49.5%) (85.2%) 200 (50.5%) (66.7%)
No (n=134) 34 (25.4%) (14.8%) 100 (74.6%) (33.3%)
HPC≥10×10
6/L Yes (n=339) 178 (52.5%) (94.2%) 161 (47.5%) (59.4%)
No (n=121) 11 (9.1%) (5.8%) 110 (90.9%) (40.6%)
HPC≥20×10
6/L Yes (n=296) 166 (56.1%) (87.8%) 130 (43.9%) (48.0%)
No (n=164) 23 (14.0%) (12.2%) 141 (86.0%) (52.0%)
HPC≥50×10
6/L Yes (n=231) 143 (61.9%) (75.7%) 88 (38.1%) (32.5%)
No (n=229) 46 (20.1%) (24.3%) 183 (79.9%) (67.5%)
*Percent within the row;
�Percent within the column.
Parameters of decision CD34+ cells ≥1×10
6/kg CD34+ cells < 1×10
6/kg
Table 5. Clinical implications for peripheral blood progenitor cells collection where the decision to commence apheresis is modi-
fied by peripheral blood WBC, MNC, or HPCture forms to be counted (19, 26, 27). Previous studies report-
ed a strong correlation between PB HPC and PB CD34+ cell
counts (25, 28), and we have reported a strong correlation
between HPC enumerated by Sysmex SE-9000 and CD34+
cells in the leukapheresis products from data on 32 patients
(20). This strong correlation led us to investigate the clinical
usefulness of HPC as a screening test to decide when to com-
mence PBPC collection. 
In the present study, we confirmed that there are statisti-
cally significant but weak correlations between PB WBC or
MNC and collected CD34+ cell count. The correlation bet-
ween PB HPC and CD34+ cells in an apheresis product was
higher than that between WBC or MNC and CD34+ cells.
However, the kinetics of PB HPC and CD34+ cells collected
did not have a similar configuration. To translate these find-
ings into the clinical practice setting, we used a ROC curve
to determine the best cutoff value of PB HPC for predicting
a target yield of CD34+ cells (≥1 or 2×106/kg). The ROC
curve revealed that the cutoff point for optimal sensitivity and
specificity was 50×106/L for target CD34+cells ≥1×106/kg
and 55×106/L for target CD34+cells ≥2×106/kg. The cut-
off values for different target values of CD34+ cells were very
close, just the HPC count difference of 5×106/L. So the abil-
ity of PB HPC to discriminate between PBPC yield ≥1×
106 CD34+ cells/kg and 2×106 CD34+ cells/kg is negligi-
ble. Among those collections with CD34+ cell yield ≥1×
106/kg, 75.5% had HPC level ≥50×106/L. In the present
study, the positive predictive value of HPC ≥50×106/L was
59.7% and the negative predictive value of that was 81.1%
for target CD34+ cell yield ≥1×106/kg. These predictive
values rely on the proportion of patients who reach the target
PBPC yield: the proportion of harvests reaching the target
yield of 1×106/kg was 42.4%. In our series, the majority of
patients had been heavily pretreated with alkylating agents,
so the proportion of patients who achieved the target CD34+
cells in apheresis was small. In the previous studies, the pos-
itive predictive values of different cutoff levels of PB HPC
ranging from 5 to 80×106/L changed from 80% to 100%
(25, 29). This is caused by the difference in the study popula-
tion. In the study of Yu et al., 16.7% of the patients were
healthy stem cell donors, and 80% of the collections reached
the target yield of ≥1×106/kg (29). These predictive values
of HPC should be applied to a similar population of patients
for which those percentages of harvests are expected to reach
the target CD34+ cells.
We compared the 6 options for deciding when to commence
PBPC collection to achieve CD34+ cells ≥1×106/kg. The
criterion of PB HPC count ≥10×106/L had the lowest false
negative rate and that of PB WBC count ≥5×109/L had the
highest false positive rates. The PB HPC count ≥50×106/L
had better predictive values and the lowest false positive rates
compared with those of the PB WBC count ≥5×109/L, ≥
10×109/L or PB HPC count ≥10×106/L, but the negative
predictive value of HPC ≥50×106/L was a little bit inferior
to that of the HPC count ≥10×106/L. 
The optimal strategy to prevent unnecessary harvesting
while minimizing the risk of missing an adequate harvest
would be different according to the patients’ premobilization
characteristics. For patients who are deemed to have poor PB-
PC collection, such as patients who have had prior exposure
to alkylating agents and radiation therapy (30, 31), the reduc-
tion of the risk of missing an adequate harvest is more impor-
tant. So applying a criterion that has the lowest false negative
rate, such as HPC count ≥10×106/L, would be appropriate
not to miss possible adequate PBPC collection. On the other
hand, for patients who seem to be good PBPC yielders, the
use of a PB HPC count that had the highest positive predic-
tive value and the lowest false positive rate, such as HPC count
≥50×106/L would be better to avoid a harvest with poor
PBPC yield.
In our study, we could not check the levels of PB CD34+
cells, which have been reported to be the best predictor of
PBPC yields. So, we could not compare the clinical usefulness
of PB WBC, MNC, and HPC with that of PB CD34+ cell
counts to decide when to commence PBPC collection.
In conclusion, the current study suggested that the correla-
tion between PB HPC and CD34+ cells in an apheresis pro-
duct is better than the correlation between PB WBC or
MNC and CD34+ cell collection. In the clinical practice
setting, incorporating the data on the PB WBC, MNC, and
HPC counts and applying variable cutoff values of HPC,
depending on patient factors that could affect PBPC mobi-
lization, would be a useful and rapid tool to predict the opti-
mal timing of PBPC collection.
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